Sarepta Therapeutics (SRPT) Posts Q2 Loss of 85c/Share

Sarepta Therapeutics (NASDAQ: SRPT) reported Q2 EPS of ($0.85), which may not compare with the analyst estimate of ($0.76). Revenue for the quarter came in at $2.58 million versus the consensus estimate of $4.3 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• AZN spikes 6% after report it denies AstraZeneca-BMS merger talks
• Capital Southwest Corporation (CSWC) Tops Q2 EPS by 2c
• BioNTech SE (BNTX) Misses Q2 EPS by 18c